Tonix Pharmaceuticals Holding
Open
$12.89
Prev. Close
$12.89
High
$12.96
Low
$12.89
Market Snapshot
$146.03M
-1.2
-2189.85
$10.09M
142
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 142 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
emptyResult
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 142 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Recently from Cashu
Tonix Pharmaceuticals Proposes 2026 Stock Incentive Plan to Boost Employee Engagement and Growth
Tonix Pharmaceuticals' New Initiative to Enhance Employee Engagement Tonix Pharmaceuticals Holding recently files for shareholder approval of a new 2026 Stock Incentive Plan, a significant step design…
Tonix Pharmaceuticals Uplists to Nasdaq, Aiming for Growth Amid Market Challenges
Tonix Pharmaceuticals: A Strategic Uplisting and Its Implications for Growth Tonix Pharmaceuticals Inc. recently completes its uplisting to the Nasdaq Global Select Market, a significant milestone aim…
Tonix Pharmaceuticals Achieves Nasdaq Uplisting, Faces Initial Share Price Decline
Tonix Pharmaceuticals’ Nasdaq Uplisting Marks a Strategic Milestone Tonix Pharmaceuticals Inc. achieves a significant milestone by uplisting to the Nasdaq Global Select Market, a decision aimed at boo…
Tonix Pharmaceuticals Advances TNX-4800 for Innovative Lyme Disease Treatment Solutions
Tonix Pharmaceuticals Advances Innovative Approach to Lyme Disease Treatment Tonix Pharmaceuticals Holding Corp. takes significant strides in its mission to combat Lyme disease with the development of…